Drug intelligence / Profile preview

XianGui Capsules

Development stage: Unknown
Lead developer: Buchang Pharmaceuticals
Administration: Oral

Overview

XianGui Capsules is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Shanxi Buchang Pharmaceutical. It is approved in China for the treatment of cardiac and cerebral vascular diseases, including coronary heart disease, angina pectoris, and cerebral infarction. The product is composed of a combination of animal-derived and botanical ingredients, including fresh turtle (Xian Gui), Panax notoginseng (Sanqi), and Salvia miltiorrhiza (Danshen). Its therapeutic mechanism in TCM terms involves invigorating the blood, removing blood stasis, and nourishing yin, which collectively aim to improve microcirculation, reduce blood viscosity, and alleviate symptoms of vascular insufficiency.

Brand names: XianGui Capsules
Other names: Xian Gui Jiao Nang鲜龟胶囊

Beyond the preview

Go deeper on XianGui Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XianGui Capsules.

Explore the full profile